Aequus Pharmaceuticals Inc. announced the signing of an exclusive distribution agreement with SCOPE Ophthalmics. Under the distribution agreement, Aequus will receive the Canadian commercial rights to 10 unique products of SCOPE's portfolio of over-the-counter ophthalmology products including the OPTASE® range of preservative free dry eye products. Under the proposed terms of the agreement, SCOPE will supply the products while Aequus will be responsible for Canadian authorization, marketing, distribution, and sales activities.

SCOPE has a broad portfolio and pipeline of ophthalmology products that has had success in Europe and recently launched in the US. Aequus will have first right of refusal on any new products SCOPE wishes to commercialize in Canada. Aequus anticipates launching select products in SCOPE's portfolio later this year.